baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Discount Zert BRM 31.12.2024/ DE000VD1UDY9 /

2024-04-24 10:15:11 AM	Chg.+0.010	Bid10:37:09 AM	Ask10:37:09 AM	Underlying	Strike price	Expiration date	Option type
44.750EUR	+0.02%	- Bid Size: -	- Ask Size: -	BRISTOL-MYERS SQUIBB...	- -	2024-12-31	Call

GlobeNewswire 6:03 PM Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...

GlobeNewswire 1:00 PM Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...

GlobeNewswire 05-22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 05-22 Anavex Life Sciences Announces Expansion of Leadership Team

GlobeNewswire 05-16 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 05-15 Lantheus Announces Executive Appointments to Accelerate Innovation

GlobeNewswire 05-14 Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...

GlobeNewswire 05-14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 05-13 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 05-08 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Immunocore reports first quarter financial results and provides a business update

GlobeNewswire 05-07 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...

GlobeNewswire 05-02 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...

GlobeNewswire 05-01 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

GlobeNewswire 05-01 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...

GlobeNewswire 04-30 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

GlobeNewswire 04-30 CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical D...

GlobeNewswire 04-25 International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...

GlobeNewswire 04-25 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...

GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 04-22 ArriVent Appoints Kristine Peterson to its Board of Directors

GlobeNewswire 04-08 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...

GlobeNewswire 04-08 Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

GlobeNewswire 04-08 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H.,...

GlobeNewswire 04-08 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

BVT Discount Zert BRM 31.12.2024/ DE000VD1UDY9 /

If you wish to receive reply to your feedback, please provide your email address.